Israel Englander Satsuma Pharmaceuticals, Inc. Transaction History

Millennium Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 14, 2023	BUY	$0.61 - $5.06 $68,855 - $571,162	112,878 Added 181.72%	174,994 $157,000
Q3 2022 Nov 14, 2022	BUY	$4.19 - $7.95 $260,266 - $493,822	62,116 New	62,116 $373,000
Q4 2021 Feb 14, 2022	SELL	$4.15 - $6.24 $249,448 - $375,073	-60,108 Closed	0 $0
Q3 2021 Nov 15, 2021	SELL	$4.54 - $7.17 $370,804 - $585,609	-81,675 Reduced 57.61%	60,108 $280,000
Q2 2021 Aug 16, 2021	BUY	$4.8 - $7.25 $608,894 - $919,684	126,853 Added 849.65%	141,783 $1 Million
Q1 2021 May 17, 2021	BUY	$4.57 - $7.18 $68,230 - $107,197	14,930 New	14,930 $88,000
Q4 2020 Feb 16, 2021	SELL	$3.56 - $5.09 $163,496 - $233,763	-45,926 Closed	0 $0
Q3 2020 Nov 16, 2020	BUY	$3.85 - $28.47 $149,133 - $1.1 Million	38,736 Added 538.75%	45,926 $179,000
Q2 2020 Aug 14, 2020	BUY	$16.01 - $34.69 $115,111 - $249,421	7,190 New	7,190 $207,000
Q4 2019 Feb 14, 2020	SELL	$9.32 - $19.68 $326,554 - $689,547	-35,038 Closed	0 $0
Q3 2019 Nov 14, 2019	BUY	$14.98 - $16.9 $524,869 - $592,142	35,038 New	35,038 $525,000

Ticker STSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 31,587,500
Description
Satsuma Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, developing novel therapeutic products for the acute treatment of migraines. The company's lead product candidate is STS101, a drug-device combination of a proprietary dry-powder formulation of dihydroergotamine mesylate, which is in SUMMIT Phase 3 efficacy trials and can ...

Get notified when there are updates to the investment portfolio of Millennium Management LLC, based on Form 13F filings with the SEC.

Stay updated on Millennium Management LLC and Israel Englander with notifications on news.